Literature DB >> 25481255

Genetic defects of the CYP21A2 gene in girls with premature adrenarche.

N Skordis1,2,3, C Shammas1, A A P Phedonos1, A Kyriakou2,4, M Toumba5, V Neocleous1, L A Phylactou6.   

Abstract

OBJECTIVES: To seek evidence on the prevalence of CYP21A2 genetic defects and consequences in girls with premature adrenarche (PA).
METHODS: The study included 59 girls diagnosed with PA. Direct DNA sequencing and MLPA analysis were performed to identify mutations in CYP21A2 gene.
RESULTS: Twelve girls were diagnosed with non-classic congenital adrenal hyperplasia (NC-CAH) based on stimulated 17-hydroxyprogesterone (17-OHP) levels and the presence of two mutations in CYP21A2, 19 were heterozygotes. The most frequent mutations detected were the mild p.Val281Leu and p.Pro453Ser. Higher levels of mean stimulated 17-OHP were found in the carriers of the p.Val281Leu mutation. The detection rate for two CYP21A2 mutations was higher in girls with PA than in adult females with hyperandrogenemia in our studied population. A notable increased allelic frequency for the known p.Asn493Ser polymorphism was observed in the pool of the 28 girls with PA in whom no mutation was identified.
CONCLUSIONS: In girls with PA, the frequency of the underlying CYP21A2 genetic defects is similar to that observed in other populations. The carrier status is likely a contributing factor in the genotype-phenotype correlation in NC-CAH. However, polymorphisms and other genes may be implicated in the clinical manifestation of the disease.

Entities:  

Keywords:  21-Hydroxylase deficiency; CYP21A2; Congenital adrenal hyperplasia; Premature adrenarche

Mesh:

Substances:

Year:  2014        PMID: 25481255     DOI: 10.1007/s40618-014-0223-1

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  34 in total

Review 1.  Congenital adrenal hyperplasia.

Authors:  Phyllis W Speiser; Perrin C White
Journal:  N Engl J Med       Date:  2003-08-21       Impact factor: 91.245

2.  High frequency of nonclassical steroid 21-hydroxylase deficiency.

Authors:  P W Speiser; B Dupont; P Rubinstein; A Piazza; A Kastelan; M I New
Journal:  Am J Hum Genet       Date:  1985-07       Impact factor: 11.025

3.  Endocrine profile and phenotype-genotype correlation in unrelated patients with non-classical congenital adrenal hyperplasia.

Authors:  Nicos Skordis; Christos Shammas; Elisavet Efstathiou; Katerina Kaffe; Vassos Neocleous; Leonidas A Phylactou
Journal:  Clin Biochem       Date:  2011-05-24       Impact factor: 3.281

4.  Mutational spectrum of steroid 21-hydroxylase and the genotype-phenotype association in Middle European patients with congenital adrenal hyperplasia.

Authors:  V Dolzan; J Sólyom; G Fekete; J Kovács; V Rakosnikova; F Votava; J Lebl; Z Pribilincova; S M Baumgartner-Parzer; S Riedl; F Waldhauser; H Frisch; M Stopar-Obreza; C Krzisnik; T Battelino
Journal:  Eur J Endocrinol       Date:  2005-07       Impact factor: 6.664

5.  Molecular model of human CYP21 based on mammalian CYP2C5: structural features correlate with clinical severity of mutations causing congenital adrenal hyperplasia.

Authors:  Tiina Robins; Jonas Carlsson; Maria Sunnerhagen; Anna Wedell; Bengt Persson
Journal:  Mol Endocrinol       Date:  2006-06-20

6.  Influence of different genotypes on 17-hydroxyprogesterone levels in patients with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency.

Authors:  T A Bachega; A E Billerbeck; J A Marcondes; G Madureira; I J Arnhold; B B Mendonca
Journal:  Clin Endocrinol (Oxf)       Date:  2000-05       Impact factor: 3.478

7.  Predicting phenotype in steroid 21-hydroxylase deficiency? Comprehensive genotyping in 155 unrelated, well defined patients from southern Germany.

Authors:  N Krone; A Braun; A A Roscher; D Knorr; H P Schwarz
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

8.  A multicenter study of women with nonclassical congenital adrenal hyperplasia: relationship between genotype and phenotype.

Authors:  P W Speiser; E S Knochenhauer; D Dewailly; F Fruzzetti; J A Marcondes; R Azziz
Journal:  Mol Genet Metab       Date:  2000-11       Impact factor: 4.797

9.  Hyperandrogenism in carriers of CYP21 mutations: the role of genotype.

Authors:  Osnat Admoni; Shosh Israel; Idit Lavi; Michal Gur; Yardena Tenenbaum-Rakover
Journal:  Clin Endocrinol (Oxf)       Date:  2006-06       Impact factor: 3.478

10.  A sequence variation in 3'UTR of CYP21A2 gene correlates with a mild form of congenital adrenal hyperplasia.

Authors:  S Menabò; A Balsamo; L Baldazzi; M Barbaro; A Nicoletti; V Conti; P Pirazzoli; A Wedell; A Cicognani
Journal:  J Endocrinol Invest       Date:  2011-04-26       Impact factor: 4.256

View more
  4 in total

1.  Variations in the 3'UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia.

Authors:  Vassos Neocleous; Pavlos Fanis; Meropi Toumba; Alexia A P Phedonos; Michalis Picolos; Elena Andreou; Tassos C Kyriakides; George A Tanteles; Christos Shammas; Leonidas A Phylactou; Nicos Skordis
Journal:  Int J Endocrinol       Date:  2017-04-12       Impact factor: 3.257

Review 2.  Non-Classic Disorder of Adrenal Steroidogenesis and Clinical Dilemmas in 21-Hydroxylase Deficiency Combined with Backdoor Androgen Pathway. Mini-Review and Case Report.

Authors:  Marta Sumińska; Klaudia Bogusz-Górna; Dominika Wegner; Marta Fichna
Journal:  Int J Mol Sci       Date:  2020-06-29       Impact factor: 5.923

3.  Children with premature pubarche: is an alterated neonatal 17-Ohp screening test a predictive factor?

Authors:  Paolo Cavarzere; Margherita Mauro; Monica Vincenzi; Silvana Lauriola; Francesca Teofoli; Rossella Gaudino; Diego Alberto Ramaroli; Rocco Micciolo; Marta Camilot; Franco Antoniazzi
Journal:  Ital J Pediatr       Date:  2018-01-16       Impact factor: 2.638

Review 4.  Polycystic ovarian syndrome in adolescents: From diagnostic criteria to therapeutic management.

Authors:  Nicolas C Nicolaides; Andreas Matheou; Florentia Vlachou; Vassos Neocleous; Nicos Skordis
Journal:  Acta Biomed       Date:  2020-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.